Gland Pharma · NSE: GLAND · BSE: 543245
Q1 FY23 results · Apr–Jun 2022
Gland Pharma reported revenue from operations of ₹856.90 crore (down 25.7% from Q1 FY22) and net profit of ₹229.17 crore (down 34.6% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 856.90 | 1,153.90 | −25.7% | 1,103.01 | −22.3% |
| Other income | 74.39 | 61.84 | +20.3% | 65.23 | +14.0% |
| Total income | 931.29 | 1,215.74 | −23.4% | 1,168.25 | −20.3% |
| Profit before tax | 308.50 | 471.84 | −34.6% | 380.48 | −18.9% |
| Net profit for the period | 229.17 | 350.65 | −34.6% | 285.90 | −19.8% |
| EPS, basic (₹) | 13.93 | 21.41 | −34.9% | 17.40 | −19.9% |
| Net margin (%) | 26.7 | 30.4 | 25.9 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 856.90 | 1,153.90 | −25.7% | 1,103.01 | −22.3% |
| Other income | 74.39 | 61.84 | +20.3% | 65.23 | +14.0% |
| Total income | 931.29 | 1,215.74 | −23.4% | 1,168.25 | −20.3% |
| Profit before tax | 308.78 | 471.86 | −34.6% | 380.56 | −18.9% |
| Net profit for the period | 229.45 | 350.68 | −34.6% | 285.98 | −19.8% |
| EPS, basic (₹) | 13.95 | 21.41 | −34.8% | 17.41 | −19.9% |
| Net margin (%) | 26.8 | 30.4 | 25.9 |
Consolidated
- Filed with BSE
- 20 Jul 2022, 16:57 IST
- Board meeting
- 20 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 20 Jul 2022, 16:57 IST
- Board meeting
- 20 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE